The link between AstraZeneca vaccination and blood clot formation has not been proven, but is possible
The European Medicines Agency (EMA) issued this statement today, 31 March.
“To date, studies have not identified specific risk factors, such as age, gender or past blood clotting problems, for these rare occurrences. A causal link has not been proven, but is possible, so further analysis is needed”, – the agency said.
At the same time, the EMA reiterated that the benefits of the AstraZeneca vaccine in terms of preventing coronavirus infection with hospitalisation and death outweigh the risks of side-effects.
As reported by News Front, the British company AstraZeneca decided to change the name of its vaccine to Vaxzevria to avoid negative perceptions due to the many deaths and side effects. The EMA pharmacovigilance risk assessment committee is meeting today to discuss the next steps. Updated vaccine recommendations are expected to be published on 6-9 April.